Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2022

Alhomoud M, Williams A, Magro C, Van Besien K, Vesole DH, Laurence J. Use of eculizumab in autologous hematopoietic stem cell transplantation-associated thrombotic microangiopathy in two adults. Leuk Lymphoma. 2022;63(2):473-477.

Guo P, Liu Y, Geng F, Daman AW, Liu X, Zhong L, et al. Histone variant H3.3 maintains adult haematopoietic stem cell homeostasis by enforcing chromatin adaptability. Nat Cell Biol. 2022;24(1):99-111.

Hsien S, Dayton JD, Chen D, Stock A, Bacha E, Cushing MM, et al. Hemostatic efficacy of pathogen-reduced platelets in children undergoing cardiopulmonary bypass. Transfusion. 2022;62(2):298-305.

Kadri S, Sboner A, Sigaras A, Roy S. Containers in Bioinformatics: Applications, Practical Considerations, and Best Practices in Molecular Pathology. J Mol Diagn. 2022;24(5):442-454.

Rajappa P, Eng KW, Bareja R, Bander ED, Yuan M, Dua A, et al. Utility of multimodality molecular profiling for pediatric patients with central nervous system tumors. Neurooncol Adv. 2022;4(1):vdac031.

Du W, Adkisson C, Ye X, Duran CL, Selvanesan BC, Gravekamp C, et al. SWIP-a stabilized window for intravital imaging of the murine pancreas. Open Biol. 2022;12(6):210273.

Alnajar H, Ravichandran H, Rendeiro AF, Ohara K, Zoughbi WA, Manohar J, et al. Tumor-immune microenvironment revealed by Imaging Mass Cytometry in a metastatic sarcomatoid urothelial carcinoma with a prolonged response to pembrolizumab. Cold Spring Harb Mol Case Stud. 2022;8(3).

Musselman K, Laurence J, Magro C, Rahbari P, Di Vitantonio T, Havryliuk Y. Atypical hemolytic uremic syndrome after myomectomy: A case report. Case Rep Womens Health. 2022;35:e00424.

Shouval R, Fein JA, Cho C, Avecilla ST, Ruiz J, Tomas AA, et al. The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT. Blood Adv. 2022;6(5):1525-1535.

Xiang G, Wang S, Chen L, Song M, Song X, Wang H, et al. UBR5 targets tumor suppressor CDC73 proteolytically to promote aggressive breast cancer. Cell Death Dis. 2022;13(5):451.